Current status of immunological therapies for prostate cancer

Keyphrases

• Phase II Study 100%
• Prostate Cancer 100%
• Immunologic Therapy 100%
• Docetaxel 66%
• Sipuleucel-T 66%
• Metastatic Castration-resistant Prostate Cancer (mCRPC) 66%
• Survival Benefit 66%
• Prostatic Acid Phosphatase 66%
• Tumor 33%
• Patient Demographics 33%
• Placebo 33%
• Prednisone 33%
• Allogeneic 33%
• Cancer Immunotherapy 33%
• Moving Forward 33%
• Clinical Development 33%
• DNA Vaccine 33%
• Immune Tolerance 33%
• Dendritic Cell-based Immunotherapy 33%
• Immune Checkpoint 33%
• Combination Immunotherapy 33%
• FDA-approved Drugs 33%
• Early Disease 33%
• Two-agent 33%
• Therapeutic Vaccine 33%
• Conventional Therapy 33%
• Induced Tolerance 33%
• Immunotherapy Strategy 33%
• Disease Burden 33%
• Emergent Paradigm 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Cancer 100%
• Immunotherapy 100%
• Docetaxel 33%
• Sipuleucel T 33%
• Castration Resistant Prostate Cancer 33%
• Acid Phosphatase Prostate Isoenzyme 33%
• Disease 33%
• Placebo 16%
• DNA Vaccine 16%
• Tumor Cell Vaccine 16%
• Rilimogene Galvacirepvec 16%
• Neoplasm 16%
• Prednisone 16%

Immunology and Microbiology

• Immunotherapy 100%
• Sipuleucel-T 50%
• Prostate 50%
• Vaccine Efficacy 25%
• Immune Tolerance 25%
• Dendritic Cell Immunotherapy 25%
• Prednisone 25%
• DNA Vaccine 25%
• Disease Burden 25%
• Tumor Cell Vaccine 25%
• Rilimogene Galvacirepvec 25%
• Cancer Immunotherapy 25%